Boehringer links up with Phenomic AI on stroma-rich cancer drugs

Canada-headquartered Phenomic AI yesterday revealed a strategic collaboration and licensing agreement with family-owned German pharma major Boehringer Ingelheim to discover targets important in stroma-rich cancers.

The companies plan to leverage Phenomic’s expertise in target identification and stromal biology based on its scTx single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers.

Under the agreement, Boehringer has the option to license targets discovered and functionally validated by Phenomic as a basis for novel cancer therapeutics. Boehringer will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer therapies.